Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.32 USD
Change Today +0.01 / 0.16%
Volume 237.9K
SPPI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 11:32 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

spectrum pharmaceuticals inc (SPPI) Key Developments

Spectrum Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Fiscal 2015; Reports Continued Advancement of Robust, Late-Stage Pipeline

Spectrum Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues were $38.62 million against $40.12 million a year ago. Loss from operations was $21.66 million against $24.41 million a year ago. Loss before income taxes was $25.42 million against $27.56 million a year ago. Net loss was $25.56 million against $27.64 million a year ago. Diluted loss per share was $0.39 against $0.44 a year ago. Non-GAAP loss from operations was $3.803 million against income of $1.969 million a year ago. Non-GAAP net loss was $4.65 million against income of $0.691 million a year ago. Non-GAAP diluted loss per share was $0.07 against $0.01 a year ago. The company expects to exit 2015 with cash and cash equivalents of more than $100 million. The company announced significant progress in the first quarter on two potential blockbusters and two near-term NDA’s: SPI-2012, a novel long-acting GCSF: Positive Phase 2 data presented at Analyst Day, and final Phase 3 protocols have been sent to the FDA. Poziotinib, a novel pan-HER inhibitor: Compelling Phase 1 data presented in breast cancer patients who had failed multiple other HER-2 directed therapies; multiple Phase 2 studies underway. EVOMELA™(CE-Melphalan), a propylene-glycol free Melphalan with improved stability; NDA review ongoing with positive FDA discussions; on track for approval decision on October 23, 2015. Apaziquone, apotentpro-drug for non-muscle invasive bladder cancer: Statistically significant results presented from an integrated analysis of two completed Phase 3 studies; NDA submission planned in 2015.

Spectrum Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 07, 2015

Spectrum Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 07, 2015

Spectrum Pharmaceuticals, Inc. Announces Results of Clinical Study of the Stability of Captisol-Enabled Melphalan

Spectrum Pharmaceuticals, Inc. announced results of a clinical study of the stability of Captisol-enabled Melphalan versus the currently marketed, propylene glycol-containing melphalan formulation entitled, 'Solution Stability of Captisol-enabled Melphalan vs Marketed Melphalan Products'. This is but one of the company's products that has a diversified portfolio of commercial, late-stage and early-stage development stage products. Data from the study show that EVOMELA has significantly better stability in solution compared to the marketed melphalan formulations. Reconstituted solution in vials is 17X more stable, and the admixture solution in bags is 5X more stable, respectively, than the same solutions prepared using currently marketed formulations.

Spectrum Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Spectrum Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of USD 51.861 million compared to USD 41.518 million a year ago. Loss from operations was USD 1.632 million compared to USD 6.510 million a year ago. Loss before income taxes was USD 3.044 million compared to USD 3.623 million a year ago. Net loss was USD 2.976 million compared to USD 39.372 million a year ago. Basic and diluted loss per share was USD 0.05 compared to USD 0.63 a year ago. Non-GAAP income from operations was USD 8.385 million compared to USD 3.454 million a year ago. Non-GAAP net income was USD 7.523 million compared to USD 3.470 million a year ago. Diluted non GAAP income per share was USD 0.09 compared to USD 0.05 a year ago. For the year, the company reported total revenues of USD 186.830 million compared to USD 155.854 million a year ago. Loss from operations was USD 31.569 million compared to USD 38.785 million a year ago. Loss before income taxes was USD 43.533 million compared to USD 36.636 million a year ago. Net loss was USD 45.719 million compared to USD 62.134 million a year ago. Basic and diluted loss per share was USD 0.71 compared to USD 1.02 a year ago. Non-GAAP income from operations was USD 24.886 million compared to non GAAP loss from operations of USD 4.919 million a year ago. Non-GAAP net income was USD 21.358 million compared to non GAAP net loss of USD 5.641 million a year ago. Diluted non GAAP income per share was USD 0.27 compared to diluted non GAAP loss per share of USD 0.09 a year ago.

Spectrum Pharmaceuticals, Inc. Presents at 12th Annual BIO Asia International Conference, Mar-24-2015 01:00 PM

Spectrum Pharmaceuticals, Inc. Presents at 12th Annual BIO Asia International Conference, Mar-24-2015 01:00 PM. Venue: Grand Hyatt Hotel, Tokyo, Japan.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPPI:US $6.32 USD +0.01

SPPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $7.39 USD +0.01
CTI BioPharma Corp $1.72 USD -0.02
GlaxoSmithKline SAE £11.52 EGP 0.00
Progenics Pharmaceuticals Inc $5.48 USD -0.06
Rigel Pharmaceuticals Inc $3.55 USD -0.13
View Industry Companies
 

Industry Analysis

SPPI

Industry Average

Valuation SPPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.2x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SPECTRUM PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.